Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.
Intra-Cellular Therapies shares fell after the company announced that the FDA canceled the advisory committee meeting to discuss the New Drug Application for the schizophrenia drug lumateperone.
Alkermes Plc said the company’s long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Privately held Pear Therapeutics said the company raised $64 million from investors, including Singapore’s Temasek Holdings, weeks after launching a mobile app for treating patients with substance use disorder.
Acer Therapeutics in-licensed the clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist osanetant from Sanofi. MyoKardia regained global rights to all the programs that the company had inked with Sanofi.
Intra-Cellular Therapies Inc. announced that the U.S. Food and Drug Administration accepted for review the biopharmaceutical company’s New Drug Application for lumateperone, an investigational agent for the treatment of schizophrenia.
Seattle-based Impel NeuroPharma closed on a Series D financing totaling $67.5 million, co-led by KKR and Northwest Venture Partners.
Alkermes Plc’s schizophrenia drug ALKS 3831 met the main goal of keeping in check a common side effect of antipsychotic medicines – weight gain – taking the company one step closer to a marketing approval for the experimental treatment.
Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.